eTHoS piles pressure on haemorrhoidopexy
Surgical innovation strives to address the perceived shortcomings and potential pitfalls associated with traditional therapeutic techniques. New devices are often recommended to patients on the basis of incomplete clinical datasets that highlight specifi c short-term gains over standard treatment but may not confi rm longterm benefi t. Enthusiasm for new technology in surgery should be balanced by the requirement to undertake objective, high-quality studies to establish the overall clinical and economic eff ect of surgical therapies. 1 In The Lancet, Angus Watson and colleagues present eTHoS, 2 a randomised, non-blinded, multicentre, phase 3 study assessing clinical outcomes and cost-eff ectiveness for treatment of moderate or severe haemorrhoids using novel stapled haemorrhoidopexy versus the longestablished traditional excisional haemorrhoidectomy. 2 These outcomes are of importance as each year millions of people are aff ected by haemorrhoids worldwide; 3 the UK National Health Service carries out in excess of 20 000 haemorrhoidal treatments. 4 Traditional haemorrhoidectomy excises symptomatic tissue from the anal canal leaving wounds that usually take 6 weeks to heal. 5 Surgeons often contend that traditional haemorrhoidectomy is a good treatment for haemorrhoids, the axiom of "6 weeks' pain for 5 years' gain" has long been touted, although surprisingly little high-quality evidence exists to support this position. 6 Patients experience short-term discomfort after traditional haemorrhoidectomy until their anal canal wounds heal, and, if severe, this pain might give rise to additional problems such as a fear of evacuation, constipation, and an inability to pass urine requiring catheterisation.
Stapled haemorrhoidopexy was specifi cally developed to tackle the problem of early pain after traditional haemorrhoidectomy. 7 A ring of tissue is excised from the relatively insensate, viscerally innervated upper anal canal, with the cut edges simultaneously brought together and fi xed by a circle of staples. Traction draws the prolapsing haemorrhoids into the anal canal where they remain fi xed (pexy). Stapling might also interrupt the submucosal blood fl ow to haemorrhoids, thereby reducing symptoms of bleeding. Initial experience reinforced the view that stapled haemorrhoidopexy was less painful for patients than traditional haemorrhoidectomy, however, severe unexpected complications were also reported, most notably chronic anal pain and rectovaginal fi stula. 8, 9 A large number of procedures have been done worldwide, and 14 000 cases have been published, 10 but the effi cacy of stapled haemorrhoidectomy in relation to traditional haemorrhoidectomy remains unknown. 11 Between 2011 and 2014, eTHoS randomised 777 patients with symptomatic grade 2-4 haemorrhoids to stapled haemorrhoidopexy (n=389) or traditional haemorrhoidectomy (n=388) at 32 UK sites. 2 Patients who had previously not responded well to treatment with rubber band ligation or haemorrhoidal artery ligation were eligible, in addition to cases where such techniques were deemed unsuitable on account of large size. Previous traditional haemorrhoidectomy or stapled haemorrhoidopexy constituted exclusions. The primary outcome comprised serial assessment of quality of life with the use of EuroQol 5 dimensions (EQ-5D) over a 2-year period, expressed as the area under the curve (AUC), so capturing both early and late eff ects of surgery.
The investigators showed that EQ-5D AUC (24 months) was signifi cantly higher (better) in the traditional haemorrhoidectomy group than in the novel stapled haemorrhoidopexy (mean diff erence -0·073 [95% CI -0·140 to -0·006]; p=0·0342). Stapled haemorrhoidopexy was much more expensive than traditional haemorrhoidectomy, with respective mean costs of £941 (SD 415) per patient versus £602 (507) for traditional excisional haemorrhoidectomy, leading to higher cost per quality-adjusted life-year for stapled haemorrhoidopexy. Notably, use of expensive modern energy devices for traditional haemorrhoidectomy 12 was precluded in eTHoS. In the immediate postoperative period, stapled haemorrhoidopexy provided superior quality of life compared with traditional haemorrhoidectomy for up to 6 weeks. Participants reported better pain scores for stapled haemorrhoidopexy at 1 and 3 weeks, but by 6 weeks, any benefi t was lost. This early benefi t for stapled haemorrhoidopexy was subsequently overshadowed by consistent medium-term and longer term gains for traditional haemorrhoidectomy. At 12 and 24 months EQ-5D unequivocally favoured traditional haemorrhoidectomy. Traditional haemorrhoidectomy consistently improved (reduced) Cleveland incontinence scores and haemorrhoid symptom scores by a small but signifi cant margin. The proportion of patients who reported that their haemorrhoids had recurred at 12 months was only 14% (39/278) for traditional haemorrhoidectomy compared with 32% (94/295) for stapled haemorrhoidopexy.
Complication rates were reassuringly similar and low for both procedures, a testimony to the high quality of surgery delivered throughout the trial. No episodes of rectal perforation occurred. At 12 months, the debilitating symptom of tenesmus regularly aff ected (ie, always or often) 13% (38/295) of patients who had stapled haemorrhoidopexy compared with 4% (11/278) who had traditional haemorrhoidectomy.
These fi ndings add to those of the HubBLe study. 13 Together HubBLe and eTHoS have set a benchmark for assessment of technological innovation across the spectrum of haemorrhoidal disease. In both studies, the novel pexy approach has proven inferior to conventional treatment. For mild to moderate haemorrhoids, haemorrhoidal artery ligation was no better than a course of banding but incurred much more cost. 13 For moderate to severe haemorrhoids, although stapled haemorrhoidopexy produced less short-term pain than traditional haemorrhoidectomy, longer term outcomes were worse and costs much more. 2 Since 2007, the National Institute for Health and Care Excellence (NICE) has recommended use of stapled haemorrhoidopexy for patients with prolapsed haemorrhoids; the only qualifi er being that surgery was considered a suitable treatment. 14 In retrospect, this approval was premature as even then, available evidence pointed to higher failure and reintervention rates for stapled haemorrhoidopexy than for traditional haemorrhoidectomy. Cost-eff ectiveness was also questioned at the time. Although innovation is to be encouraged, unproven devices should be assessed in the context of suitable prospective clinical studies as NICE belatedly acknowledged in dealing with use of colonic stents for obstructing bowel cancer. 15 Finally, and long overdue, these studies provide high-quality information for patients with haemorrhoids on what to expect after standard surgical treatment; 5 weeks' pain with a high probability of at least 2 years gain. The search continues for an eff ective painless approach to haemorrhoid treatment.
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